Global pharmaceutical & biotechnology outlook 2013 japan pharma - Reports Corner
Upcoming SlideShare
Loading in...5
×
 

Global pharmaceutical & biotechnology outlook 2013 japan pharma - Reports Corner

on

  • 676 views

The coming years will see Japan pharma regaining its status as innovator driven with Edoxaban for Daiichi Sankyo, Canagliflozin for Mitsubishi Tanabe, and Dolutegravir for Shionogi bringing the good ...

The coming years will see Japan pharma regaining its status as innovator driven with Edoxaban for Daiichi Sankyo, Canagliflozin for Mitsubishi Tanabe, and Dolutegravir for Shionogi bringing the good times back for the respective companies in 2013 and carrying enough potential to change global market dynamics in the anticoagulant, diabetes and HIV space resp. We think that the massive ~$45b poured in acquiring innovation by Japanese companies does not justify its value as we find that the key catalysts from Japan are in-house candidates.

https://www.reportscorner.com/reports/10015/Global-Pharmaceutical-&-Biotechnology-Outlook-2013:-Japan-Pharma/

Statistics

Views

Total Views
676
Views on SlideShare
676
Embed Views
0

Actions

Likes
0
Downloads
13
Comments
0

0 Embeds 0

No embeds

Accessibility

Upload Details

Uploaded via as Microsoft PowerPoint

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

Global pharmaceutical & biotechnology outlook 2013 japan pharma - Reports Corner Global pharmaceutical & biotechnology outlook 2013 japan pharma - Reports Corner Presentation Transcript

  • RCReports CornerGlobal Pharmaceutical & Biotechnology Outlook2013: Japan Pharma
  • DescriptionDescriptionReports Cornerwww.reportscorner.comThe coming years will see Japan pharma regaining its status asinnovator driven with Edoxaban for Daiichi Sankyo, Canagliflozinfor Mitsubishi Tanabe, and Dolutegravir for Shionogi bringing thegood times back for the respective companies in 2013 andcarrying enough potential to change global market dynamics inthe anticoagulant, diabetes and HIV space resp. We think that themassive ~$45b poured in acquiring innovation by Japanesecompanies does not justify its value as we find that the keycatalysts from Japan are in-house candidates.
  • Brief SummaryBrief SummaryReports Cornerwww.reportscorner.comThe coming years will see Japan pharma regaining its status asinnovator driven with Edoxaban for Daiichi Sankyo, Canagliflozinfor Mitsubishi Tanabe, and Dolutegravir for Shionogi bringing thegood times back for the respective companies in 2013 andcarrying enough potential to change global market dynamics inthe anticoagulant, diabetes and HIV space resp. We think that themassive ~$45b poured in acquiring innovation by Japanesecompanies does not justify its value as we find that the keycatalysts from Japan are in-house candidates. Changing politicalscenario in Japan will accelerate the pace of reforms in Japan asrecently; the Liberal Democratic Party (LDP) of Japan came backinto power replacing the short tenure of the Democratic Party ofJapan (DPJ). LDP was the pioneer initiator of major healthcarereforms with a focus on curbing healthcare costs by means ofenhancing generic drugs penetration. Our report discusses indetails about the implications of these changes on Innovator andgeneric domestic Japanese pharma companies.
  • Brief SummaryBrief SummaryReports Cornerwww.reportscorner.comGlobal companies on the other hand are going to see a favorablescenario in coming years - expected launches in 2013-2014 fromglobal companies will increase competition to domestic playersmainly in the respiratory, oncology and rheumatoid arthritistherapy areas, and will increase overall market size of Diabetesand Osteoporosis markets.Going forward, for 2013 –Generic companies will continue towitness a growth story, we think that the recent incentives topromote generic uptake have played out well and at current levels,we do not see meaningful growth until early 2014 when new set ofincentives will start playing off. However, in the related space –drug chain stores and biogenerics are two new arenas which wesee as next growth drivers – we have analyzed these two novelspaces as well in this report.
  • Brief SummaryBrief SummaryReports Cornerwww.reportscorner.comThe detailed 146 pages report on Japan Pharma contains:I. Performance in 2012 – The Hits & MissesII. Japan Pharma: Looking forward in 2013 and beyondStand on individual companiesChanging political scenario is likely to accelerate the pace ofreformsIII. Analysis on Innovators Companies – Innovation andconsolidation continue to serve as catalystRich looking pipeline could be delusiveKey R&D catalysts from Japan pharmaKey upcoming milestonesExpected upcoming launches from global companies in Japanand its implicationsLikely implications of recent consolidation activitiesSustainability thru increasing overseas baseIV. Analysis on Generic Companies
  • Brief SummaryBrief SummaryReports Cornerwww.reportscorner.com2012 – price cuts & implicationsNew layer of reforms playing out wellDominance of big players in dispensing pharmacyShrinking general practitioners marketDPC hospitals are a new growth avenueV. Analysis on Drug Chain StoresMacro forces favoring Drug Chain StoresSuccess story from a few, likely to be replicated by followersVI. Analysis on Biogeneric CompaniesEvolving Biogenerics space in JapanIN-DEPTH COMPANY ANALYSIS AND REPORTS ONDaiichi Sankyo- Edoxaban will bequeath wings to the priceKyorin – Respiratory Franchise Strengthening UpMitsubishi Tanabe- Canagliflozin is key, but other drivers also inqueueShionogi- Dolutegravir brings the good times back
  • Brief SummaryBrief SummaryReports Cornerwww.reportscorner.comEisai- HAYABUSA challenging to achieve despite new approvalsAstellas- Defensive Agreements dilute Catalysts ValueChugai – Growth story well built in priceDainippon Sumitomo- Expectation from Latuda are well built inKyowa Hakko Kirin- Upside from Potelligent technology is stillawayNippon Chemiphar - Thin margins, wavering profitability outlookSawai- Wait until next price cutsTakeda- EU Aspirations are hard to attainTowa- Solid fundamentals not sizeable in near termKEY INDUSTRY TABLES/ ANNEXURES:Japan Pharma ValuationKey Pipeline Candidates- Japan PharmaGlobal Companies expected major launches in Japan- 2013/14Consolidation activities major M & A in Japan- Last 5 YearsReforms in 2012 and Implications
  • Brief SummaryBrief SummaryReports Cornerwww.reportscorner.comRevised Incentives for PharmaciesLooming Generic OpportunityJapan Generic segmentsDrug Chain stores- Profitability TrendsKey MilestonesJapan Generic Market ModelTop 25 Products vs. Generic Threat
  • Table of ContentsTable of ContentsReports Cornerwww.reportscorner.comI. Performance in 2012 – The Hits & MissesII. Japan Pharma: Looking forward in 2013 and beyond-- Stand on individual companies-- Changing political scenari-- is likely t-- accelerate the pace of reformsIII. Analysis on Innovators Companies – Innovation and consolidationcontinue t-- serve as catalyst-- Rich Looking Pipeline Could be delusive-- Key R&D catalysts from Japan pharma-- Key upcoming milestones-- Expected upcoming launches from global companies in Japan and itsimplications-- Likely implications of recent consolidation activities-- Sustainability thru increasing overseas base
  • Table of ContentsTable of ContentsReports Cornerwww.reportscorner.comIV. Analysis on Generic Companies-- 2012 – price cuts & implications-- New layer of reforms playing out well-- Dominance of big players in dispensing pharmacy-- Shrinking general practitioners market-- DPC hospitals are new growth avenueV. Analysis on Drug Chain Stores-- Macr-- forces favoring Drug Chain Stores-- Success story from a few, likely t-- be replicated by followersVI. Analysis on Biogeneric Companies-- Evolving Biogenerics space in JapanJapan Pharma - Company Analysis1. DAIICHI SANKY-- (4569): Edoxaban Will Bequeath Wings T-- ThePrice!
  • Table of ContentsTable of ContentsReports Cornerwww.reportscorner.com• Sum of parts valuation• Lixiana/Edoxaban-Has Key Differentiating Features• Key clinical data analysis• Denosumab: Will Contribute T-- Bottom Lines Despite Partnering• Worst Is Priced In For Ranbaxy Performance• Daiichi Sanky-- Espha (DSE) - A Game Changer In Japan Generic Market2. KYORIN (4569): Respiratory Franchise Strengthening Up!• Catalyst t-- strengthen respiratory frenchise• KRP-108 – The key driver• Kipres Continues T-- Drive Growth In Anti-Asthmatic Market• Uritos Sales Ramping Up Well• Rapport with GPs Keeps Mucodyne Sales Stable:• Key In-House Candidates Look For Partners3. MITSUBISHI TANABE (4508): Canagliflozin is Key, But Other Drivers
  • Table of ContentsTable of ContentsReports Cornerwww.reportscorner.comAls-- In Queue!• Canagliflozin Is Showing Promise Of Better Safety And Efficacy• Canagliflozin : CV Safety Issues Are Manageable• Domestic Business Faces High Long-Listed Exposure, New Catalysts WillContinue T-- Grow• Remicade Franchise And Telavic Will Support Declining DomesticBusiness• Teneligliptin Set T-- Enjoy Favorable DPPIV Market In Japan• Royalty Income From Gilenya Continues T-- Grow• Avanafil Prospects Depends Upon Vivus Marketing Partner• Higher Dividend Expected During MTP4. SHIONOGI (4507): Dolutegravir Brings The Good Times Back!• Dolutegravir/comb-- approval likely in 2013• Dolutegravir - Combination Therapy Offers Wider Opportunity
  • Table of ContentsTable of ContentsReports Cornerwww.reportscorner.com• Rapidly Changing HIV Market Dynamics• Strategic Rational of Integrase Inhibitors• Crestor – NRx/TRx Show Better Resilience Post Lipitor Generics• Low Margin Domestic Business is Not Going t-- Change Soon• Pipeline Has Potential but Unlikely t-- Give Breakthroughs in Near Term• US Business – Nothing Left For Further Downside5. EISAI (4523): HAYABUSA Challenging t-- Achieve Despite NewApprovals!• Pipeline Potential Overly Built in Price• Challenges at domestic front will Surface Soon• Biomarkers Upside Is beyond HAYABUSA timeline• Aricept Lifecycle Management Programs Unlikely t-- Meet ManagementsTarget• Halaven clinical data is encouraging for triple negative breast cancer
  • Table of ContentsTable of ContentsReports Cornerwww.reportscorner.com• Fycompa prospects in US are limited due t-- genericization of the market• Belviq label will restrict its peak sales and agreement with Arena leaveslittle on bottom line6. ASTELLAS (4503): Defensive Agreements Dilute Catalysts Value!• Enzalutamide: 2013/14 Will Unfold Potential• Myrbetriq Launch Will Help Maintaining Leadership In The OAB Space• Tivozanib US Approval In RCC Is Likely But Has Limited Potential• ASP-015k Finds A Strong Partner• ASP-015k Deal Summary7. CHUGAI (4519): Growth Story Well Built In Price!• Actemra T-- Gradually Increase Its Patient Base• Pertuzumab Will Secure Approval In Japan• T-DMI Us Approval In Second Line Breast Cancer Is Likely• Safe Domestic Business And Sales Ramp Up Of Newly Launched Products
  • Table of ContentsTable of ContentsReports Cornerwww.reportscorner.com• Roches Possible Course Of Actions For Increasing Stake In Chugai8. DAINIPPON SUMITOM-- (4506): Expectations From Latuda Are WellBuilt In!• LATUDA continue t-- succeed• High Unmet Need Still Exists In The Anti-Psychotics Market• Other Pipeline Candidates9. KYOWA HAKK-- KIRIN (4151): Upside From Potelligent Technology IsStill Away!• Potelligent technology still a away from fetching premium• Business Restructuring Brings Focus on Pharma Business• Tivantinib Looses Its Commercial Attractiveness• KW-0761 – First Potelligent Based Antibody in Market10. NIPPON CHEMIPHAR (4539): Thin Margins, Wavering ProfitabilityOutlook!
  • Table of ContentsTable of ContentsReports Cornerwww.reportscorner.com• Lowest Profitability Structure Is Not Going T-- Change Soon• Increasing DPC hospitals are biggest driver11. SAWAI (4555): Wait Until Next Price Cuts!• Excellent Reach in DP Segment is Advantageous• DPC Opportunity is Yet t-- be Tapped• Bio-Similars Opportunity Placed Aside for Now• Premium valuation vs. Peers is Likely t-- be Maintained• Emerging Threats T-- Domestic Generic Companies12. TAKEDA (4502): EU Aspirations Are Hard t-- Attain!• Increasing competition in DPPIV inhibitors class• Global approval of SYR-322 and its combination is still awaited• EDARBI – Me Too ARB Will Alleviate Pain of Atacand Revenue Loss• Tofacitinib JP Approval will strengthen its RA portfolio• Nycomed acquisition helps deliver the growth and negate Actos patent expiry
  • Table of ContentsTable of ContentsReports Cornerwww.reportscorner.com• Key Global late stage Pipeline Candidates• Vortioxetine US approval is likely• Key candidates from Millennium• TAK-875 Data in The Lancet - First GPR-40 agonist Can PotentiallyAlter Diabetes Therapy Paradigm, Though a Few Questions RemainUnanswered13. TOWA (4553): Solid Fundamentals Not Sizeable In Near Term!• Modest Sales sustainability from Dispensing Pharma• Ambitious Investment Plans T-- Meet Future Demand• Emerging Threats T-- Domestic Generic CompaniesList of Charts1. Generic Penetration Trend2. Key Generic Companies: Sales Break Up3. Anticoagulants Market-2009 Vs. 2020
  • Table of ContentsTable of ContentsReports Cornerwww.reportscorner.com4. Spring- PhIII Findings (1)5. Spring- PhIII Findings (2)6. Dolutegravir PhIII Program7. E-5501 - Short And Long Term Platelet Responses8. Asp015k – Changes From Baseline In PASI At Day 429. Latuda: Monthly TRx Trend – Us10. Atypical Anti-Psychotics Market11. Atypical Anti-Psychotics – Competitive Landscape12. Japan: Long Listed Drugs And Generic Penetration (2012)13. Tak-875 PhII Efficacy Data14. Type 2 Diabetes MarketList of Tables1. Report Card – 2012 (Japan Pharma Stock Performance Hit & Miss)2. Japan Pharma Valuation
  • Table of ContentsTable of ContentsReports Cornerwww.reportscorner.com4. Key Pipeline Candidates- Japan Pharma5. Global Companies Expected Major Launches In Japan- 2013/146. Consolidation Activities Major M&A In Japan - Last 5 Years7. Japanese Global Cos Overseas Sales8. JP Companies Performance Vs. US/EU9. Reforms In 2012 And Implications10. Revised Incentives For Pharmacies11. Looming Generic Opportunity12. Key Generic Companies: Sales Break Up13. Generic Companies: Relative Standing14. Japan Generic: Segments15. Drug Chain Stores: Profitability Trend16. Biogenerics Opportunities In Japan17. Daiichi Sankyo: Datablock18. Daiichi Sankyo: Sum Of Parts
  • Table of ContentsTable of ContentsReports Cornerwww.reportscorner.com19. Daiichi Sankyo: Key Milestones20. Daiichi Sankyo: Relative Clinical Profile Of Xarelto, Eliquis And EdoxabanIn SPAF21. Daiichi Sankyo: Different Geographies22. Daiichi Sankyo: Edoxaban PhII Clinical Study In SPAF: Global; Japan;Taiwan23. Daiichi Sankyo: Baseline Characteristics Comparison Of Pivotal Trials InSPAF24. Daiichi Sankyo: Comparison Of Available Osteoporosis Treatments25. Daiichi Sankyo: Ranmark (Denosumab) - Development Status In Japan26. Daiichi Sankyo: Comparison Between Zometa And Denosumab InOncology27. Daiichi Sankyo: RBXY: Datablock28. Daiichi Sankyo: Daiichi Sanky-- Espha Approvals
  • Table of ContentsTable of ContentsReports Cornerwww.reportscorner.com29. Kyorin - Datablock30. Kyorin -Key Milestones31. Kyorin -KRP-108: Relating Composition32. Kyorin -Kipres: Competitive Landscape In Japan33. Kyorin - Japanese OBS Market34. Mitsubishi Tanabe - Datablock35. Mitsubishi Tanabe - Key Milestones36. Mitsubishi Tanabe – SGLT2 Pipeline (Japan And Global Status)37. Mitsubishi Tanabe – SGLT2 Inhibitors- Clinical Data Comparison38. Mitsubishi Tanabe - Key Products39. Mitsubishi Tanabe - Japan RA Market40. Mitsubishi Tanabe - HCV Pipeline (Japan)41. Mitsubishi Tanabe - Marketed DPP4 In Japan42. Mitsubishi Tanabe - DPP4 Pipeline* (Japan And Global Status)
  • Table of ContentsTable of ContentsReports Cornerwww.reportscorner.com42. Mitsubishi Tanabe - DPP4 Pipeline* (Japan And Global Status)43. Mitsubishi Tanabe - Avanafil : Relative Positioning44. Mitsubishi Tanabe - Dividend Estimates45. Mitsubishi Tanabe - Key Pipeline Candidates46. Shionogi - Datablock47. Shionogi - Key Milestones48. Shionogi - Single Trial Data49. Shionogi - Dolutegravir – PhIII Trials50. Shionogi - HIV Marketed Drugs51. Shionogi - HIV Pipeline Drugs52. Shionogi - Spring-2 Trial Data53. Shionogi - Dolutegravir NPV- Shionogi54. Eisai - Datablock55. Eisai - Key Milestones56. Eisai - Key Pipeline Candidates
  • Table of ContentsTable of ContentsReports Cornerwww.reportscorner.com57. Eisai - Aricept WW Sales Projections58. Eisai - Aricept Sales In Japan: Strength Wise59. Eisai - Halaven – A Number Of Indications Underway60. Eisai - Upcoming Competitors For Halaven61. Eisai - Fycompa Clinical Data62. Eisai - Data Presented At IEC Annual Meeting 201163. Eisai - Eritoran Vs. Xigris: Comparative Efficacy64. Astellas - Datablock65. Astellas - Key Milestones66. Astellas - Long-Term PhI/II Follow-Up Results67. Astellas - Overactive Bladder Syndrome: Key Drugs68. Astellas - Mirabegron Efficacy And Tolerability Results In European And Australian Patients69. Astellas - Mirabegron Efficacy And Tolerability Results In North AmericanPatients70. Astellas - Competitive Landscape: Advanced Renal Cell Carcinoma
  • Table of ContentsTable of ContentsReports Cornerwww.reportscorner.com71. Astellas - Select Oral Ra/Psoriasis Drugs In Development72. Chugai - Datablock73. Chugai - Key Milestones74. Chugai - Actemra - Ongoing Global Trials75. Chugai - Japan RA Market76. Chugai - Efficacy And Safety Comparison Of TDM1 Vs.Trastuzumab+Docetaxel In First Line BC TDM1: Ongoing ImportantClinical Studies Of T-DM1 In Late Stage Her 2 Positive Breast Cancer77. Chugai - Chugai-Sales Break Up78. Dainippon Sumitom-- - Datablock79. Dainippon Sumitom-- - Key Milestones80. Dainippon Sumitom-- - Psychiatrists See High Unmet Need81. Dainippon Sumitom-- - Lurasidone - Ongoing/Planned Clinical Studies82. Dainippon Sumitom-- - Pearl 2 Data
  • Table of ContentsTable of ContentsReports Cornerwww.reportscorner.com83. Dainippon Sumitom-- - Pearl 3 Vs. Seroquel: Overall- A Good Risk/BenefitRatio84. Dainippon Sumitom-- - Latuda SWOT Analysis85. Dainippon Sumitom-- - Pearl 3 Extension Study Data- Non Inferior ToSeroquel XR86. Dainippon Sumitom-- - Dainippon Sumitomo-Key Pipeline Candidates87. KHK - Datablock88. KHK - Key Milestones89. KHK -Potelligent Technology90. KHK -Segment Classification91. KHK -Income Statement92. KHK -Pharma Sales Trend93. Nippon Chemiphar - Datablock94. Nippon Chemiphar - Entry Of Foreign Companies In Japan Generic Market
  • Table of ContentsTable of ContentsReports Cornerwww.reportscorner.com95. Nippon Chemiphar - Generic Companies: Relative Valuation96. Sawai - Datablock97. Sawai - Excellent Reach In Various Markets98. Sawai - Reforms In 2012 And Implications99. Sawai - Sawai Vs. Key Competitors Sales Break Up Key100. Sawai - Generic Companies: Relative Valuation101. Sawai - Foreign Companies Entry In Japan Generic Market102. Takeda -Datablock103. Takeda -Antidepressants – Ww Competitive Landscape104. Takeda -PhIII Data Summary- Vortioxetine105. Takeda -Antidepressants: Key Pipeline Candidates AndIssues106. Takeda -Antidepressants Market In Japan107. Takeda -Key Attributes Of Major Anti-Diabetic Drugs
  • Table of ContentsTable of ContentsReports Cornerwww.reportscorner.com108. Takeda -Advantage, Disadvantage Of Key Anti-Diabetic109. Drugs105.akeda -Antidepressants: Key Pipeline Candidates AndIssues106. Takeda -Antidepressants Market In Japan107. Takeda -Key Attributes Of Major Anti-Diabetic Drugs108. Takeda -Advantage, Disadvantage Of Key Anti-Diabetic109. Drugs111. Takeda -Tak-875 Ph II Trial Design112. Datablock113. Reforms In 2012 And Implications114. Towa Vs. Key Competitors Sales Break Up Key115. Foreign Companies Entry In Japan Generic Market116. Revenue Growth Of Generic Cos. In Price Cut Years
  • Table of ContentsTable of ContentsReports Cornerwww.reportscorner.comAnnexures1. Key Milestones- Japan Pharma2. Japan Generic Market Model3. Top 25 Products Vs. Generic Threat4. Daiichi Sanky-- - Domestic Pharma Sales Trend5. Mitsubishi Tanabe - Long Listed Product Sales As % Of Total DomesticSales6. Shionogi - Viking- PhII Findings7. Shionogi - Spring- PhIII Findings8. Shionogi - Single- PhIII Findings9. Shionogi - Dolutegravir PhIII Program10. Eisai - Consolidated Income Statement: MPe Vs. Hayabusa11. Eisai - Domestic Pharma Sales12. Eisai - Belviq Cost T-- Eisai
  • Table of ContentsTable of ContentsReports Cornerwww.reportscorner.com13. Astellas - Xtandi: NPV Shrinks Due T-- Commercialization Agreement14. Chugai - Possibilities Of Roche Increasing Its Stake In Chugai Are Real &High15. Chugai - Roche-Chugai: Maturing Relationship Timeline16. Chugai - Potential Benefits T-- Roche By Increasing Stake In Chugai17. Chugai - Widening Prospects Of Actemra18. Chugai - Domestic Japan Pharma Sales19. Dainippon Sumitom-- – Dainippon Sumitomo- Key Pipeline Candidates20. Dainippon Sumitom-- - Dainippon Sumitomo-Key Pipeline Candidates21. Sawai - Generic Companies: Relative Standing22. Takeda - Key Pipeline Candidates110. Takeda -Ongoing Clinical Trials Of Tak-875111. Takeda -Tak-875 Ph II Trial Design112. Datablock
  • Table of ContentsTable of ContentsReports Cornerwww.reportscorner.com113. Reforms In 2012 And Implications114. Towa Vs. Key Competitors Sales Break Up Key115. Foreign Companies Entry In Japan Generic Market116. Revenue Growth Of Generic Cos. In Price Cut YearsAnnexures1. Key Milestones- Japan Pharma2. Japan Generic Market Model3. Top 25 Products Vs. Generic Threat4. Daiichi Sanky-- - Domestic Pharma Sales Trend5. Mitsubishi Tanabe - Long Listed Product Sales As % Of Total DomesticSales6. Shionogi - Viking- PhII Findings7. Shionogi - Spring- PhIII Findings8. Shionogi - Single- PhIII Findings
  • Table of ContentsTable of ContentsReports Cornerwww.reportscorner.com9. Shionogi - Dolutegravir PhIII Program10. Eisai - Consolidated Income Statement: MPe Vs. Hayabusa11. Eisai - Domestic Pharma Sales12. Eisai - Belviq Cost T-- Eisai13. Astellas - Xtandi: NPV Shrinks Due T-- Commercialization Agreement14. Chugai - Possibilities Of Roche Increasing Its Stake In Chugai Are Real &High15. Chugai - Roche-Chugai: Maturing Relationship Timeline16. Chugai - Potential Benefits T-- Roche By Increasing Stake In Chugai17. Chugai - Widening Prospects Of Actemra18. Chugai - Domestic Japan Pharma Sales19. Dainippon Sumitom-- – Dainippon Sumitomo- Key Pipeline Candidates20. Dainippon Sumitom-- - Dainippon Sumitomo-Key Pipeline Candidates21. Sawai - Generic Companies: Relative Standing
  • Table of ContentsTable of ContentsReports Cornerwww.reportscorner.com22. Takeda - Key Pipeline Candidates104. Tada -PhIII Data Sumy- Vortioxetine105. Takeda -Antidepressants: Key Pipeline Candidates AndIssues106. Takeda -Antidepressants Market In Japan107. Takeda -Key Attributes Of Major Anti-Diabetic Drugs108. Takeda -Advantage, Disadvantage Of Key Anti-Diabetic109. Drugs110. Takeda -Ongoing Clinical Trials Of Tak-875111. Takeda -Tak-875 Ph II Trial Design112. Datablock113. Reforms In 2012 And Implications114. Towa Vs. Key Competitors Sales Break Up Key115. Foreign Companies Entry In Japan Generic Market
  • Table of ContentsTable of ContentsReports Cornerwww.reportscorner.com116. Revenue Growth Of Generic Cos. In Price Cut YearsAnnexures1. Key Milestones- Japan Pharma2. Japan Generic Market Model3. Top 25 Products Vs. Generic Threat4. Daiichi Sanky-- - Domestic Pharma Sales Trend5. Mitsubishi Tanabe - Long Listed Product Sales As % Of Total DomesticSales6. Shionogi - Viking- PhII Findings7. Shionogi - Spring- PhIII Findings8. Shionogi - Single- PhIII Findings9. Shionogi - Dolutegravir PhIII Program10. Eisai - Consolidated Income Statement: MPe Vs. Hayabusa11. Eisai - Domestic Pharma Sales
  • Table of ContentsTable of ContentsReports Cornerwww.reportscorner.com12. Eisai - Belviq Cost T-- Eisai13. Astellas - Xtandi: NPV Shrinks Due T-- Commercialization Agreement14. Chugai - Possibilities Of Roche Increasing Its Stake In Chugai Are Real &High15. Chugai - Roche-Chugai: Maturing Relationship Timeline16. Chugai - Potential Benefits T-- Roche By Increasing Stake In Chugai17. Chugai - Widening Prospects Of Actemra18. Chugai - Domestic Japan Pharma Sales19. Dainippon Sumitom-- – Dainippon Sumitomo- Key Pipeline Candidates20. Dainippon Sumitom-- - Dainippon Sumitomo-Key Pipeline Candidates21. Sawai - Generic Companies: Relative Standing22. Takeda - Key Pipeline Candidates
  • For more informationFor more informationReports Cornerwww.reportscorner.comFor more information please visit our websitehttps://www.reportscorner.com/reports/10015/Global-Pharmaceutical-&-Biotechnology-Outlook-2013:-Japan-Pharma/
  • Reports CornerThank YouThank Youwww.reportscorner.comRCContact us: contact@reportscorner.com